Protein disulfide isomerase mediates integrin-dependent adhesion  by Lahav, J. et al.
Protein disul¢de isomerase mediates integrin-dependent adhesion
J. Lahava;b;*, N. Gofer-Dadosha;b, J. Luboshitza;b, O. Hessa;b, M. Shaklaia;b
aCoagulation Laboratory, Institute of Haematology, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel
bSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Received 29 March 2000; received in revised form 15 May 2000
Edited by Shmuel Shaltiel
Abstract Cell adhesion is mediated by the integrin adhesion
receptors. Receptor^ligand interaction involves conformational
changes in the receptor, but the underlying mechanism remains
unclear. Our earlier work implied a role for sulfhydryls in
integrin response to ligand binding in the intact blood platelet.
We now show that non-penetrating blockers of free sulfhydryls
inhibit L1 and L3 integrin-mediated platelet adhesion regardless
of the affinity state of the integrin. Removal of the inhibitors
prior to adhesion fully restores adhesion despite the irreversible
nature of inhibitor^thiol interaction, indicating sulfhydryl ex-
posure in response to adhesion. We further show that blocking
protein disulfide isomerase (PDI) inhibits adhesion. These data
indicate that: (a) ecto-sulfhydryls are necessary for integrin-
mediated platelet adhesion; (b) disulfide exchange takes place
during this process; (c) surface PDI is involved in integrin-
mediated adhesion. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Adhesion of platelets to components of the exposed suben-
dothelium is a necessary step in blood coagulation. A major
adhesion pathway employed by platelets as well as by many
other cells is mediated by the heterodimeric adhesion recep-
tors integrins [1,2]. Thus integrins K2L1, K5L1 and KIIbL3 are
the platelet adhesion receptors for collagen, ¢bronectin and
¢brinogen, respectively [2]. The a⁄nity of puri¢ed integrins,
or of integrins in cell lysate, to their ligands is considerably
low and the interaction can be disrupted by weak non-ionic
detergents [3] or EDTA [4]. However, accumulating evidence
indicates that integrin a⁄nity for their ligands is tightly regu-
lated by the cell and that under di¡erent conditions, integrins
may present di¡erent a⁄nity states [5^7]. These di¡erent af-
¢nity states are manifests of di¡erences in the conformation of
the integrin, as accessibility to speci¢c monoclonal antibodies
re£ects the competence of the integrin to bind to its ligand
[7,9]. Ligand-occupied integrins express yet an additional set
of epitopes inaccessible on the unoccupied integrin [8,10], im-
plying further changes in integrin conformation upon ligand
binding. We have shown that, in contrast to cell lysate, when
the integrin K2L1 on intact whole platelets interacts with its
collagen ligand, the complex cannot be disrupted by deter-
gents, nor by EDTA. Only a reducing agent in combination
with detergent or low pH disrupts the K2L1^collagen complex
[11]. This observation suggests involvement of disul¢de
bridges in the change in conformation upon ligand binding.
Little is known about the mechanism leading to changes in
conformation. It has been shown that ligand binding results in
metal ion displacement [12], and in receptor aggregation [13].
Our observation that platelet adhesion to collagen leads to
irreversible binding of the ligand to its integrin receptor sug-
gests that ligand binding evoked disul¢de exchange or the
involvement of free sulfhydryls on the integrin [11]. Expres-
sion of protein disul¢de isomerase (PDI) on the surface of
several cell types, including the blood platelet, had been dem-
onstrated [14], suggesting an enzymatic mediator for disul¢de
exchange in the cell-surface receptors and making such a
mechanism for ligand-induced change in the conformation
of the integrin conceptually plausible. In the work presented
here, we demonstrate that indeed surface sulfhydryls are cru-
cial for L1 and L3 integrin-mediated adhesion of the platelet
and that PDI is involved in this process.
2. Materials and methods
2.1. Materials
N-Ethyl-maleimide (NEM), para-chloro-mercuriphenyl sulfonic
acid (pCMPS), bacitracin, bovine serum albumin (BSA) (cat. no.
A7638) non-immune rabbit serum and control mouse ascites were
obtained from Sigma (Israel), thiolyte monobromotrimethyl-ammo-
niobimane (qBBr) from Calbiochem, acid soluble calf skin collagen
from Worthington, human plasma ¢brinogen, 97% clottable, from
Kabi-Pharmacia. Human plasma ¢bronectin was puri¢ed from fresh
plasma according to Engvall and Ruoslahti [15].
Polyclonal rabbit anti-bovine PDI antiserum, which cross reacts
with human PDI [16], was a generous gift from Dr. N.J. Bulleid
(Department of Biochemistry and Molecular Biology, University of
Manchester, Manchester, UK), monoclonal anti-rat PDI (RL-90)
which recognizes human PDI [17] was purchased from Alexis Bio-
chemicals (Switzerland). L1-Activating antibody TS2/16 [5] was kindly
donated by Dr. M.A. Schwartz and L3-activating antibody LIBS6 [10]
was kindly donated by Dr. M.H. Ginsberg, both from the Depart-
ment of Vascular Biology, The Scripps Research Institute, La Jolla,
CA, USA. Blocking antibodies 6F1 (for K2L1) [18] and 10E5 (for
KIIbL3) [19] were a generous gift from Dr. Barry Coller of the Depart-
ment of Medicine, Mount Sinai Medical Center, New York, USA.
Blocking antibody P1D2 (for K5L1) [20] was purchased from Chem-
icon International Inc., Temecula, CA, USA.
2.2. Platelet preparation and adhesion
Platelet suspensions in bu¡er (2U107 pl/ml) were prepared either by
gel ¢ltration [11,21] or by washing [22], and their adhesion to protein-
covered plastic, blocked with BSA, was measured according to pub-
lished methods [11,21]. Inhibitors were added to the platelets 10 min
prior to introduction of the platelets to the adhesive surface. When
reversibility of the inhibitory e¡ect was tested, the inhibitor was added
to 2U108 pl/ml, incubated 10 min and the platelet suspension diluted
10 times with either bu¡er alone or bu¡er containing the inhibitor.
Untreated platelets were always included as controls. When the e¡ect
of antibodies (monoclonal L1-activating antibody TS2/16 [5] and L3-
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activating antibody LIBS6 [23], polyclonal rabbit anti-bovine PDI [16]
and monoclonal anti-PDI clone RL-90 [17], integrin-blocking mono-
clonal 6F1 anti-K2L1 [18], 10E5 anti-KIIbL3 [19] and P1D2 anti-K5L1
[20]) was tested, antiserum or ascites £uid were diluted 1:100 in gel
¢ltration bu¡er and were incubated with the platelets for 30 min at
room temperature before addition to the adhesion surface. Platelets
incubated under the same conditions with non-immune rabbit serum
or control mouse ascites, diluted 1:100 with the same bu¡er, were
used as control. Adhesion in the presence of 10 Wg/ml integrin-block-
ing antibodies was less than 10% of that of control.
3. Results
3.1. Blocking free sulfhydryls
The e¡ect of sulfhydryl blockers on platelet adhesion to
¢brinogen, collagen and ¢bronectin was measured using one
membrane-penetrating reagent (NEM) and two non-penetrat-
ing reagents (pCMPS and qBBr). We found that L1 and L3
integrin-mediated adhesion was inhibited when free sulfhy-
dryls were blocked (Fig. 1). The very e¡ective inhibition of
the non-penetrating reagents indicated that the relevant sulf-
hydryls were extracellular. The inhibitory e¡ect was concen-
tration-dependent on all substrates studied and by all reagents
used (data not shown).
The a⁄nity of integrins to their ligand can be manipulated
in vitro by ‘activating’ agents such as certain antibodies [5,10]
and Mn2 ions [24] which bind on the outside and lead to
increase in ligand a⁄nity and to induction of epitope expres-
sion which correlate with these a⁄nity changes. Conversion to
the high a⁄nity state by extracellular Mn2 ions or activating
antibodies was demonstrable on all substrates (but not on
BSA) (Fig. 2). In order to test whether sulfhydryls are neces-
sary for conversion to high a⁄nity or for ligand binding, we
treated resting platelets with pCMPS before or after the addi-
tion of Mn2 ions or activating antibodies. We found that
blocking the ecto-sulfhydryls either before or after integrin
conversion to the high a⁄nity state inhibited both L1 and
L3 integrin-mediated adhesion (Fig. 2).
3.2. Reversibility of inhibition
All the blockers used in this study interact irreversibly with
free sulfhydryls and can be removed only by reducing agents
[25,26]. Nonetheless, we observed that if the platelet suspen-
sion was exposed to the sulfhydryl blockers and then diluted
10-fold to reduce the concentration of the reagent, adhesion
was fully restored (Fig. 3).
3.3. E¡ect of PDI
The mechanism by which free sulfhydryls become available
during platelet adhesion was tested by measuring adhesion in
the presence of the membrane-impermeable, commonly used
PDI inhibitor bacitracin [17,27]. As shown in Fig. 4A, baci-
tracin at 3 mM was an e¡ective inhibitor of adhesion. The
e¡ect of bacitracin was concentration-dependent (data not
shown). The speci¢city of PDI involvement was further cor-
roborated by use of function-blocking antibodies to PDI. Two
di¡erent antibodies were used, a polyclonal and a monoclo-
nal, and adhesion in their presence was compared with adhe-
sion in the presence of equal dilutions of non-immune rabbit
serum and non-immune mouse ascites £uid, respectively. As
shown in Fig. 4B, both antibodies inhibited platelet adhesion
to all substrates, indicating that PDI is involved in integrin-
mediated platelet adhesion.
4. Discussion
We thus show, for the ¢rst time, that blocking free sulf-
Fig. 1. Inhibition of platelet adhesion by sulfhydryl blockers. Gel-¢l-
tered platelets were treated with membrane-penetrating (NEM,
10 WM) and non-penetrating (pCMPS, 125 WM; qBBr, 10 mM) irre-
versible thiol blockers and their adhesion to immobilized matrix
proteins in the absence or presence of the blockers was measured by
counting bound platelets. The e¡ect of each thiol blocker was calcu-
lated relative to adhesion of untreated platelets to the same sub-
strate. Adhesion to BSA-covered substrates was less than 1% in all
experiments.
Fig. 2. Integrins in high a⁄nity state are also inhibited by non-pen-
etrating thiol blockers. A: Mn2 (1 mM)-treated platelets adhere in
greater numbers than untreated platelets. Non-penetrating pCMPS
(125 WM) added either before or after Mn2 blocked adhesion. B:
L1-Activating antibody TS2/16 (in ascites, diluted 1:100) and L3-ac-
tivating antibody LIBS6 (Fab fragment) increase platelet adhesion
to ¢brinogen, collagen and ¢bronectin. Addition of pCMPS
(125 WM) either before or after 30 min incubation with the antibod-
ies blocked platelet adhesion (relative to the e¡ect of ascites control
where relevant). Neither Mn2 nor activating antibodies had an ef-
fect on adhesion to BSA (not shown).
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hydryls on the platelet surface inhibits platelet adhesion to
collagen, ¢bronectin and ¢brinogen. Adhesion to these adhe-
sive proteins is mediated by integrins K2L1, K5L1 and KIIbL3,
respectively [28^30]. Inhibition was achieved by three di¡erent
thiol blockers: NEM, an irreversible, membrane-penetrating
blocker; pCMPS, an irreversible, membrane-non-penetrating
mercurial agent [25], and qBBr, an irreversible, membrane-
impermeable alkylating agent [26]. Thus, both L1 and L3 in-
tegrin-mediated adhesion of the platelet depends on ecto-sulf-
hydryls. Adhesion of human skin ¢broblasts to collagen and
¢bronectin, which is mediated by the same L1 integrins as on
the platelets, was also inhibited by pCMPS and bacitracin
(Hess and Lahav, unpublished observations), suggesting that
involvement of sulfhydryls in integrin-mediated adhesion is
shared by several cell types.
In 1968, Aledort et al. [31] showed that the membrane-im-
permeable thiol blocker pCMPS inhibits adenosine diphos-
phate-mediated platelet aggregation in platelet-rich plasma.
Subsequently, Ando and Steiner [32] reported that the mem-
brane-permeable radioactive para-chloromercuribenzoic acid
labeled several proteins on isolated platelet membranes, which
were not further characterized. These early observations indi-
cated that sulfhydryls of the human platelet membrane play a
role in platelet^platelet interaction and that there were several
candidates for the role. However, using the weakly £uorescent
non-penetrating agent qBBr, Kalomiris and Coller [33] failed
to demonstrate the presence of free sulfhydryls on the surface
of intact human platelets. Thus, it appeared that while plate-
let^platelet interaction could be inhibited by impermeable thi-
ol blockers, the relevant proteins could only bind the sulfhy-
dryl reagent if the membrane had been disrupted. An e¡ect of
sulfhydryl blockers on cell^cell interaction was also reported
for neutrophils, where Schwartz and Harlan have shown that
membrane sulfhydryls are involved in adhesion to endothe-
lium [34].
In our earlier work, we reported that when intact live plate-
lets interacted with ¢brillar collagen, a fraction of the K2L1
integrin could be eluted from its ligand only if the disruption
of the ionic interaction was preceded by the disruption of
disul¢de bonds [11]. This observation suggested that disul¢de
bonds formed on the intact cell as a consequence of receptor^
ligand interaction. The inhibitory e¡ect of pCMPS and qBBr
on platelet adhesion to collagen reported here (Fig. 1) corrob-
orates this suggestion, and their inhibitory e¡ect on adhesion
to ¢bronectin and ¢brinogen (Fig. 1) implies that this may be
a common mechanism for integrins. The ‘reversibility’ of in-
hibition for all three reagents (Fig. 3A) and substrates (Fig.
3B) indicates that no toxicity was involved. It also suggests
that in the resting state of the platelet, no free sulfhydryls are
accessible to the blocking agent and, therefore, their removal
prior to exposure to the ligand left no e¡ect. In the process of
ligand^receptor interaction, however, either disul¢de exchange
or exposure of buried sulfhydryl takes place, and sulfhydryl
blockers can interact with the forming sulfhydryls thereby
blocking any subsequent disul¢de-stabilized conformation.
This would also account for the lack of labeling of resting
intact platelets by qBBr [33], a ¢nding we amply replicated
(Gofer-Dadosh and Lahav, unpublished results), and for our
observation [11] that dithiothreitol was needed to elute K2L1
from its ligand.
Fig. 4. PDI-speci¢c inhibitors block integrin-mediated adhesion. A:
Bacitracin, a non-penetrating, commonly used inhibitor of PDI, re-
versibly inhibited integrin-mediated platelet adhesion. B: Monoclo-
nal anti-rat PDI ascites that cross react with human PDI and block
its function, at 1:100 dilution, and polyclonal anti-PDI antiserum,
at 1:100 dilution, inhibit platelet adhesion to the three substrates,
relative to adhesion in the presence of control mouse ascites at simi-
lar dilutions or non-immune rabbit serum.
Fig. 3. Presence of the thiol reagent is necessary for adhesion to be
inhibited. A: Incubation of platelets with NEM (10 WM), pCMPS
(125 WM) or qBBr (10 mM) followed by 10-fold dilution of the
blocking agent prior to exposure to the adhesive substrate removed
the inhibitory e¡ect of the reagents. Continued presence of the
blocking agents at the site of adhesion was necessary for inhibition
to take place. B: Continued presence of the thiol reagent as a neces-
sary requisite for inhibition held true for both L1 and L3 integrin as
manifested by pCMPS (125 WM) e¡ect on adhesion to collagen and
¢bronectin and to ¢brinogen, respectively.
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Integrin activation by Mn2 ions or activating antibodies is
believed to be a consequence of conformational changes that
switch the receptor to a higher a⁄nity state [8,23,24]. Ligand
binding causes yet another change in conformation [10]. In-
deed, we observed here that, in the presence of Mn2 ions or
activating antibodies, platelet adhesion to all three substrates
increased, though the extent of the increase di¡ered (Fig. 2).
Treatment with pCMPS completely abolished adhesion of
Mn2- or antibody-treated platelets irrespective of the order
of addition of the reagents (Fig. 2). Together these data imply
that pCMPS acts downstream of conversion to the high a⁄n-
ity state, possibly on the process of ligand binding itself, fur-
ther supporting our working hypothesis.
For the disul¢des to form during the process of ligand bind-
ing, a catalyzing agent was likely to be active. In recent years,
cell membrane-associated PDI has been reported for several
cell types, including platelets [14], and its involvement in in-
tegrin KIIbL3-mediated platelet^platelet interaction has re-
cently been observed ([27], J. Lahav, unpublished). We there-
fore tested several membrane-impermeable PDI inhibitors for
their e¡ect on platelet adhesion. We found that the commonly
used membrane-impermeable PDI inhibitor, bacitracin, abol-
ished more than 80% of platelet adhesion to collagen, ¢bro-
nectin and ¢brinogen (Fig. 4A). The e¡ective bacitracin con-
centration was similar or lower than that reported to block
adhesion of phorbol 12-myristate 13-acetate-activated lym-
phocytes to ¢bronectin and collagen [35]. The bacitracin e¡ect
was non-toxic, as it could be reversed if the bacitracin was
washed away or diluted (Fig. 4A), in agreement with the ob-
servation of Mou et al. [35].
Polyclonal antibodies [16] and a function-blocking mono-
clonal [17] antibody against PDI also inhibited L1 and L3
integrin-mediated platelet adhesion (Fig. 4B), strongly sup-
porting our working hypothesis of the common role of PDI-
dependent disul¢de exchange in integrin-mediated adhesion.
Very few cells have yet been probed for the presence of
surface-associated PDI and it is therefore too early to assess
the generality of PDI involvement in integrin-mediated adhe-
sion. It is suggested however that at least one other cell sys-
tem, namely the lymphocyte, depends on the same mecha-
nism, since Mou et al. [35] showed that bacitracin inhibits
L1 and L7 integrin-mediated adhesion of lymphocytes to ¢bro-
nectin, collagen and laminin and Ryser et al. had reported
that PDI is present on lymphocytes [36]. We observe that
bacitracin inhibits adhesion of human skin ¢broblasts to the
same substrates as it inhibits platelet adhesion, but membrane
expression of PDI has not yet been demonstrated on these
cells. Correlation between PDI expression on the surface of
cells and sulfhydryl involvement in ligand-induced integrin-
mediated adhesion of these cells will be necessary for estab-
lishing the generality of this mechanism for ligand-induced
changes in integrin conformation.
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